Pliant Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Net Income	-210.3	-161.34	-123.32	-97.26	-41.53	Upgrade
Depreciation & Amortization	2.13	1.84	1.82	1.54	1.31	Upgrade
Loss (Gain) From Sale of Investments	2.51	-4.99	-1.81	1.26	-	Upgrade
Stock-Based Compensation	37.63	44.48	22.6	10.44	3.9	Upgrade
Other Operating Activities	3.45	2.39	1.86	1.67	0.27	Upgrade
Change in Accounts Receivable	-	1.98	0.02	7.28	-2.23	Upgrade
Change in Accounts Payable	1.43	2.97	-1.35	0.89	0.92	Upgrade
Change in Other Net Operating Assets	7.66	-3.7	5.55	-1.26	-0.15	Upgrade
Operating Cash Flow	-155.5	-116.36	-94.63	-75.44	-37.27	Upgrade
Capital Expenditures	-3.85	-0.92	-1.76	-1.95	-1.53	Upgrade
Investment in Securities	144.19	-126.09	-148.44	75.65	-209.33	Upgrade
Investing Cash Flow	140.34	-127.01	-150.2	73.7	-210.87	Upgrade
Long-Term Debt Issued	19.91	-	9.85	-	-	Upgrade
Net Debt Issued (Repaid)	19.91	-	9.85	-	-	Upgrade
Issuance of Common Stock	3.21	275.25	217.56	2.98	161.19	Upgrade
Other Financing Activities	-	-0.85	-0.56	-0.46	-	Upgrade
Financing Cash Flow	23.12	274.41	226.85	2.53	213.21	Upgrade
Net Cash Flow	7.95	31.03	-17.98	0.78	-34.93	Upgrade
Free Cash Flow	-159.35	-117.28	-96.39	-77.4	-38.8	Upgrade
Free Cash Flow Margin	-	-7422.91%	-995.26%	-1022.13%	-92.79%	Upgrade
Free Cash Flow Per Share	-2.63	-2.00	-2.29	-2.16	-1.82	Upgrade
Cash Interest Paid	2.62	1.15	0.62	-	-	Upgrade
Levered Free Cash Flow	-98.53	-66.86	-51.12	-42.56	-23.66	Upgrade
Unlevered Free Cash Flow	-96.64	-66.07	-50.62	-42.56	-23.66	Upgrade
Change in Net Working Capital	-10.19	-3.62	-6.22	-8.38	1.31	Upgrade

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q